ArticleSouthern African journal of HIV medicine2025
Urine-based assays for inpatients with HIV-associated tuberculosis in rural South Africa.
Article in Southern African journal of HIV medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prevalence and Mortality due toOpen forum infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurate non-sputum-based tuberculosis (TB) diagnostics are urgently needed to improve diagnostic yield and patient outcomes. Objectives: To compare the diagnostic accuracy and diagnostic yield of Urine Xpert Ultra (Urine-XPU) and Urine Determine Method: Adults (≥ 18 years) with HIV had sputum, urine and blood collected for comprehensive TB testing shortly after admission. Additionally, focused assessment with sonography for HIV-associated TB (FASH) was performed. The MRS was defined by Xpert Ultra or culture-based tests for Results: A total of 206 participants were enrolled, with a median age of 39 years and 63% were female. Using the MRS the sensitivity of AlereLAM was 45.2% (95% confidence interval [CI]: 31.2-60.1) and Urine-XPU, 59.5% (95%CI: 44.5-73.0); and the specificity of AlereLAM was 93.6% (95%CI: 88.2-96.6) and Urine-XPU 95.0% (95%CI: 90.0% - 97.6%). Urine-XPU and AlereLAM performed better than sputum Xpert Ultra (Sputum-XPU) in patients with more severe illness. Additionally, Urine-XPU showed potential for accurately detecting rifampicin resistance. Conclusion: Urine-XPU and AlereLAM demonstrated comparable diagnostic accuracy for TB in hospitalised adults with HIV. Integrating Urine-XPU alongside AlereLAM and Sputum-XPU may improve timely and accurate diagnosis of TB and rifampicin resistance. Further research is required to optimise the diagnosis-to-treatment pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.